Clinical Trials Logo

Clinical Trial Summary

The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01826214
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date May 2013
Completion date May 2015

See also
  Status Clinical Trial Phase
Withdrawn NCT01479582 - Providing Access to Cord Blood Units for Transplants Phase 2
Terminated NCT02145039 - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases N/A
Not yet recruiting NCT05521087 - A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Phase 1
Completed NCT02141828 - A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Phase 1
Recruiting NCT04811560 - A Study of JNJ-75276617 in Participants With Acute Leukemia Phase 1/Phase 2
Recruiting NCT01919866 - Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Phase 1/Phase 2
Not yet recruiting NCT01339988 - Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Phase 4